Making the DARPin® Difference Reality for Patients

Patrick Amstutz, CEO
Michael Stumpp, COO

Q3 2018 Interim Management Statement
November 1, 2018 – Molecular Partners AG (SIX: MOLN)

MOLECULAR partners

Disclaimer

This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. This presentation is not an offering circular within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this presentation may not be sent to countries, or distributed in or sent from countries, in which this is barred or prohibited by law. This document is not a prospectus or a prospectus equivalent document and investors should not subscribe for or purchase any securities referred to in this document. This document does not constitute a recommendation regarding the shares.

This presentation contains specific forward-looking statements, beliefs or opinions, including statements with respect to the product pipelines, potential benefits of product candidates and objectives, estimated market sizes and opportunities as well as the milestone potential under existing collaboration agreements, which are based on current beliefs, expectations and projections about future events, e.g. statements including terms like “potential”, “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Molecular Partners AG and investments and those explicitly or implicitly presumed in these statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of Molecular Partners AG cannot be relied on as a guide to future performance. Forward-looking statements speak only as of the date of this presentation and Molecular Partners AG, its directors, officers, employees, agents, counsel and advisers expressly disclaim any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this presentation. No statement in this document or any related materials or given at this presentation is intended as a profit forecast or a profit estimate and no statement in this document or any related materials or given at this presentation should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-looking statements.

Unless stated otherwise the information provided in this presentation are based on company information. This presentation is intended to provide a general overview of Molecular Partners AG’s business and does not purport to deal with all aspects and details regarding Molecular Partners AG. Accordingly, neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained in the presentation or of the views given or implied. Neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this information or its contents or otherwise arising in connection therewith.

The material contained in this presentation reflects current legislation and the business and financial affairs of Molecular Partners AG which are subject to change and audit.

Agenda

• Review & Highlights Q3 2018	Patrick Amstutz, CEO
• Deep-dive Abicipar AAO Data	Michael Stumpp, COO
• Outlook 2018 & Beyond	Patrick Amstutz, CEO
• Q&A	All

Review & Highlights Q3 2018

MOLECULAR partners

R&D Highlights 2018 to date - Oncology

- **MP0250 in MM**
  - Clinical trial ongoing in combination with bortezomib/dexamethasone
  - Dose for expansion set at 8mg/kg every 3 weeks
  - Durable responses seen in patients who came from proteasome inhibitor (PI) based pretreatment
    - ➢ MP0250 has potential to overcome adaptive resistance mechanism

- **MP0250 in EGFR mut NSCLC**
  - Clinical trial ongoing in first patient cohort
  - Initial safety data expected by year-end 2018

- **Immuno-oncology and DARPin® I/O toolbox**
  - Development candidate MP0310 (FAP x 4-1BB) to be presented at multiple scientific conferences
  - Research candidate targeting FAP x CD40 showcases toolbox value

Pipeline: A Balanced and Robust Portfolio



AMD: age-related macular degeneration; DME: diabetic macular edema; NSCLC: non-small cell lung cancer

MOLECULAR partners

Deep-dive:
Abicipar AAO Data 2018

MOLECULAR partners

Primary Endpoint: STABLE VISION Abicipar Q8 and Q12 Non-Inferior to Ranibizumab Q4 with Fewer Injections

Abicipar





PP=Per protocol; BCVA=Best Corrected Visual Acuity; BL= baseline

Allergan

Source: Allergan presentation at AAO, 26 Oct 2018

MOLECULAR partners

Clinical Trial Versus Real World Treatment Practice

Abicipar

- **Fixed monthly treatment** consistent outcomes but not used in real life practice
- **Extend injection interval to every 12 weeks** attempted to address injection and visit burden but failed with ranibizumab
- **Extend injection interval to 8 weeks** consistent outcomes but requires every 2 months injections and patient visits
- **Treat and Extend (TAE):** can lessen the burden but requires patient monitoring visits and can result in suboptimal vision outcomes



[a]Ranibizumab monthly and aflibercept bimonthly dosing unless stated. BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; FRB, Fight Retinal Blindness; PRN, q4w/q8w, 4-/8-week dosing interval; T&E, treat-and-extend; VA, visual acuity.oivc

1. Rosenfeld et al. *N Engl J Med*. 2006; **2.** Regillo et al. *AJO*. 2008; **3.** Heier et al. *Ophthalmology*. 2012; **4.** Silva et al. *Ophthalmology*. 2018; **5.** Souied et al. *Acta Ophthalmologica* 2017. **6.** Holz et al. *Br J Ophthalmol.* 2015; **7.** Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group, *Ophthalmology*. 2014. **8.** Kim et al. *Retina*. 2016.

Allergan

Source: Allergan presentation at AAO, 26 Oct 2018

MOLECULAR partners

Abicipar Q8 and Q12 in SEQUOIA and Q8 in CEDAR Non-Inferior to Ranibizumab for Key Secondary Endpoint: Mean Change in BCVA From Baseline

Abicipar



BCVA vision gain after initial loading doses maintained through week 52

Source: Allergan presentation at AAO, 26 Oct 2018

MOLECULAR partners

Mean Change in CRT From Baseline was Similar in the Abicipar Q8 and Q12 Groups and the Ranibizumab Q4 Group

Abicipar



CRT improvement after initial loading doses maintained through week 52

Source: Allergan presentation at AAO, 26 Oct 2018

MOLECULAR partners

Between Study Differences in Effect Size for the Same Therapeutic Regimen are Common

Abicipar



Aflibercept 2Q4 showed 3.3 letter difference

Aflibercept 0.5Q4 showed 2.8 letter difference

Source: Heier et al., 2012

Allergan

11

Source: Allergan presentation at AAO, 26 Oct 2018

MOLECULAR partners

‘Saw Tooth’ Profile as seen for Eylea®



Heier et al, 2012

Adverse Events of Intraocular Inflammation by Maximum Severity (SEQUOIA and CEDAR)

Abicipar

IOI AE Severity, n (%)	Abicipar 2q8 n=625	Abicipar 2q12 n=626	Ranibizumab q4 n=625
Overall IOI rate	96 (15.4)	96 (15.3)	2 (0.3)
Mild	21 (3.4)	23 (3.7)	2 (0.3)
Moderate	52 (8.3)	53 (8.5)	0
Severe	23 (3.7)	20 (3.2)	0

Most patients with IOI in the abicipar arms (82.3% and 89.6%, respectively) were treated with topical corticosteroid

Source: Allergan presentation at AAO, 26 Oct 2018

One patient had missing data; AE: adverse event; IOL: intraocular inflammation

Allergan

MOLECULAR partners

Continuous Improvement of Biologics

Abicipar

Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration

Year 1 Results of the FOCUS Study

Jeffrey S. Heier, MD; David S. Boyer, MD; Thomas A. Ciulla, MD; Philip J. Ferrone, MD; J. Michael Jumper, MD; Ronald C. Gentile, MD; Debbi Kotlovker, MS; Carol Y. Chung, PhD; Robert Y. Kim, MD; for the FOCUS Study Group

Table 4. Patients With Adverse Events

Adverse Event Category Preferred Term	Patients, No. (%) PDT Alone (n = 56)	Ranibizumab + PDT (n = 105)
Ocular Adverse Events in Study Eye in ≥10% of Patients, Either Group		
Any ocular adverse event*	56 (100)	105 (100)
Intraocular inflammation*	3 (5.4)	40 (38.1)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use LUCENTIS safely and effectively. See full prescribing information for LUCENTIS.

LUCENTIS® (ranibizumab injection) for intravitreal injection
For Intravitreal Injection
Initial U.S. Approval: 2006

Adverse Reaction	DME and DR 2-year		AMD 2-year		AMD 1-year		RVO 6-month	
	LUCENTIS 0.3 mg	Control	LUCENTIS 0.5 mg	Control	LUCENTIS 0.5 mg	Control	LUCENTIS 0.5 mg	Control
	n=250	n=250	n=379	n=379	n=440	n=441	n=259	n=260
Intraocular inflammation	4%	3%	18%	8%	13%	7%	1%	3%

Source: Allergan presentation at AAO, 26 Oct 2018

MOLECULAR partners

Conclusions – Abicipar has the Potential to be the First Fixed 12 Week anti-VEGF

Abicipar

√ SEQUOIA and CEDAR were the first successful demonstration of maintaining vision of 2q12 as a fixed treatment regimen compared to monthly ranibizumab.
- 2q12 and 2q8 met the prespecified criteria for noninferiority to monthly ranibizumab for the primary endpoint at Week 52
- >91% of abicipar patients had stable vision on both dosing regimens

√ Secondary endpoints from both SEQUOIA and CEDAR at Q8 and Q12 dosing regimen support primary endpoint results
- BCVA and CRT improvements after initial doses were maintained to week 52

√ Overall incidence of treatment-emergent adverse events was comparable among the 3 treatment arms
- Abicipar-treated patients had higher risk of developing IOI than ranibizumab-treated patients
- Majority of the cases were mild to moderate and were treated with topical corticosteroid

✓ Allergan plans to file abicipar with the FDA in 1H 2019 pending a pre-BLA meeting
✓ Allergan continues to expect results from MAPLE trial using its further optimized formulation in 1H 2019

Source: Allergan presentation at AAO, 26 Oct 2018

MOLECULAR partners

Outlook 2018 & Beyond

MOLECULAR partners

Key Messages

- Successful transition from DARPin® platform into **clinical oncology company**:
  - **MP0250** (Phase 2) demonstrated initial activity in MM and is progressing in NSCLC (EGFR-mut); additional details at ASH (Dec 01, 2018)
  - MP0274 (Phase 1) ongoing in Her2+ cancers
  - MP0310 (1st candidate from **I/O DARPin® toolbox) to enter into clinics in 2019; additional candidates to be highlighted in Q4 2018**
- **Abicipar** Phase 3 in nAMD progressing with partner Allergan:
  - Efficacy data underlined potential to be first therapeutic with fixed 12 week dosing regime
  - Further optimized formulation tested in MAPLE trial with results expected for H1 19
- **Financed into 2020** (excl. any abicipar-related proceeds), capturing key value inflection points

➢ Keep on forward integrating towards late-stage development and the market

Multiple Value Inflection Points Ahead

	2018	2019	2020
Abicipar	**nAMD: 1-y Ph 3 efficacy** ✓	Data from further optimized formulation (MAPLE trial) H1/19 FDA filing planned for H1/19 DME: Ph 3 expected start	nAMD: expected launch
MP0250	MM: initial efficacy NSCLC: initial safety	MM: efficacy NSCLC: initial efficacy	NSCLC: efficacy
MP0274	Initial safety	Additional safety and initial efficacy	
MP0310	Preclinical data	FIH	

Funding into 2020 (excl. any abicipar related proceeds)

MOLECULAR partners

Save the Date: 2nd R&D Update

- Theme: “Building Tomorrow’s Breakthroughs”
- Venue: New York, The Yale Club
- Date: December 6, 2018, 12:00pm – 2:30pm

Discussion topics :

- Development strategy for MP0250 in MM, including a guest speaker discussing the MM landscape
- Advancement of our I/O pipeline
- Our research strategy discussed by our new CSO Pamela Trail
- Latest clinical data on abicipar presented by a guest speaker from Allergan

- Ongoing updates on specific Molecular Partners’ R&D Day 2018 website
- **RSVP:** susan@sanoonan.com

Thank you

Questions?

MOLECULAR partners

Appendix

MOLECULAR partners

IR Agenda

Date	***Event***
December 6, 2018	R&D Day in New York
February 7, 2019	Publication of Full-year Results 2018 (unaudited)
March 15, 2019	Expected Publication of Annual Report 2018
April 16, 2019	Annual General Meeting
May 9, 2019	Interim Management Statement Q1 2019
August 27, 2019	Publication of Half-year Results 2019 (unaudited)
October 31 , 2019	Interim Management Statement Q3 2019

Molecular Partners AG
Wagistrasse 14
8952 Zürich-Schlieren
Switzerland
www.molecularpartners.com
T +41 44 755 77 00

MOLECULAR partners